Apollomics (APLM) Payables (2023 - 2025)

Apollomics (APLM) posted quarterly Payables of $124000.0 for Q4 2025, down 97.07% quarter-over-quarter from $4.2 million in Q4 2023.

Apollomics (APLM) Payables (2023 - 2025) Analysis & Trends

Apollomics (APLM) has reported Payables for 2 consecutive years, with $124000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Payables changed N/A year-over-year to $124000.0; the TTM figure through Dec 2025 stood at $124000.0 (changed N/A YoY), while the FY2025 annual figure was $124000.0, changed N/A from the prior year.
Payables declined to $124000.0 in Q4 2025 per APLM's latest filing, from $4.2 million in the prior quarter.
Across five years, Payables topped out at $4.2 million in Q4 2023 and bottomed at $124000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	108.02 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	428.93 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	35.57 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	622.65 Mn
10	Apollomics	34.08 Mn	30.81 Mn	-	124,000.00

Download Data